Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

被引：0
|
作者：
Kudo, Daisuke [1 ]
Komeno, Takuya [2 ]
Yoshida, Chikashi [2 ]
Tsutsumi, Ikuyo Ota [2 ]
Ohashi, Kazuteru [3 ]
Kakihana, Kazuhiko [3 ]
Kobayashi, Takeshi [3 ]
Doki, Noriko [3 ]
Najima, Yuho [3 ]
Igarashi, Aiko [3 ]
Hori, Mitsuo [4 ]
Okoshi, Yasushi [4 ,5 ]
Fujio, Takayuki [4 ]
Shinagawa, Atsushi [6 ]
Yamamoto, Masahide [7 ]
Takano, Hina [8 ]
Kumagai, Takashi [9 ]
Yamamoto, Koh [10 ]
Toyota, Shigeo [11 ]
Nakamura, Yuichi [12 ]
Kojima, Hiroshi [5 ,13 ]
机构：
[1] Tokyo Kita Med Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Mito Med Ctr, Dept Hematol, Ibaraki, Japan
[3] Komagome Hosp, Hematol Div, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[4] Ibaraki Cent Hosp, Dept Hematol, Ibaraki, Japan
[5] Univ Tsukuba Hosp, Ibaraki Clin Educ & Training Ctr, Ibaraki, Japan
[6] Hitachi Gen Hosp, Dept Hematol, Ibaraki, Japan
[7] Tokyo Med & Dent Univ Hosp, Dept Hematol, Tokyo, Japan
[8] Japanese Red Cross Musashino Hosp, Dept Hematol, Tokyo, Japan
[9] Ome Municipal Gen Hosp, Dept Hematol, Tokyo, Japan
[10] Yokohama City Minato Red Cross Hosp, Dept Hematol, Yokohama, Kanagawa, Japan
[11] Yokosuka Kyosai Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan
[12] Saitama Med Univ Hosp, Dept Hematol, Saitama, Japan
[13] Ibaraki Cent Hosp, Dept Med Oncol, Ibaraki, Japan
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113788
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2160
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial
    Tanaka, Keisuke
    Toyota, Shigeo
    Akiyama, Megumi
    Wakimoto, Naoki
    Nakamura, Yuichi
    Najima, Yuho
    Doki, Noriko
    Kakihana, Kazuhiko
    Igarashi, Aiko
    Kobayashi, Takeshi
    Ohashi, Kazuteru
    Kudo, Daisuke
    Shinagawa, Atsushi
    Takano, Hina
    Fujio, Takayuki
    Okoshi, Yasushi
    Hori, Mitsuo
    Kumagai, Takashi
    Saito, Tatsuya
    Mukae, Junichi
    Yamamoto, Koh
    Tsutsumi, Ikuyo
    Komeno, Takuya
    Yoshida, Chikashi
    Yamamoto, Masahide
    Kojima, Hiroshi
    ACTA HAEMATOLOGICA, 2019, 141 (02) : 111 - 118
  • [2] Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Moreau, Philippe
    Mary, Jean-Yves
    Attal, Michel
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (04) : 605 - 606
  • [3] Alternating bortezomib and dexamethasone as induction regimen prior to autologous stem-cell transplantation in newly-diagnosed younger patients with multiple myeloma: Results of a PETHEMA phase II trial.
    Rosinol, Laura
    Oriol, Albert
    Victoria Mateos, M.
    Sureda, Anna
    Diaz-Mediavilla, Joaquin
    Alegre, Adrian
    Lahuerta, Juan-Jose
    De La Rubia, Javier
    Herrero, Carlos
    Van de Velde, Helgi
    San Miguel, J. F.
    Blade, Joan
    BLOOD, 2006, 108 (11) : 879A - 880A
  • [4] A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation
    Girnius, Saulius K.
    Lee, Saem
    Kambhampati, Suman
    Rose, Michal G.
    Mohiuddin, Abid
    Houranieh, Antoun
    Zimelman, Abraham
    Grady, Terrence
    Mehta, Paulette
    Behler, Caroline
    Hayes, Teresa G.
    Efebera, Yvonne A.
    Prabhala, Rao H.
    Han, Andrew
    Yellapragada, Sarvari V.
    Klein, Catherine E.
    Roodman, Garson D.
    Lichtenstein, Alan
    Munshi, Nikhil C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (01) : 36 - 43
  • [5] Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
    Harousseau, Jean-Luc
    Attal, Michel
    Leleu, Xavier
    Troncy, Jacques
    Pegourie, Brigitte
    Stoppa, Anne-Marie
    Hulin, Cyrille
    Benboubker, Lofti
    Fuzibet, Jean-Gabriel
    Renaud, Marc
    Moreau, Philippe
    Avet-Loiseau, Herve
    HAEMATOLOGICA, 2006, 91 (11) : 1498 - 1505
  • [6] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    M Cavo
    L Pantani
    A Pezzi
    M T Petrucci
    F Patriarca
    F Di Raimondo
    G Marzocchi
    M Galli
    V Montefusco
    E Zamagni
    B Gamberi
    P Tacchetti
    A Brioli
    A Palumbo
    P Sonneveld
    Leukemia, 2015, 29 : 2429 - 2431
  • [7] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Cavo, M.
    Pantani, L.
    Pezzi, A.
    Petrucci, M. T.
    Patriarca, F.
    Di Raimondo, F.
    Marzocchi, G.
    Galli, M.
    Montefusco, V.
    Zamagni, E.
    Gamberi, B.
    Tacchetti, P.
    Brioli, A.
    Palumbo, A.
    Sonneveld, P.
    LEUKEMIA, 2015, 29 (12) : 2429 - 2431
  • [8] Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Premilinary results of an IFM phase II study
    Harousseau, JL
    Attal, M
    Coiteux, V
    Stoppa, AM
    Hulin, C
    Benboubker, L
    Fuzibet, JG
    Renard, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 598S - 598S
  • [9] Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
    Morgan, Gareth J.
    Davies, Faith E.
    Gregory, Walter M.
    Bell, Sue E.
    Szubert, Alexander J.
    Coy, Nuria Navarro
    Cook, Gordon
    Feyler, Sylvia
    Johnson, Peter R. E.
    Rudin, Claudius
    Drayson, Mark T.
    Owen, Roger G.
    Ross, Fiona M.
    Russell, Nigel H.
    Jackson, Graham H.
    Child, J. Anthony
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 442 - 450
  • [10] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
    Muranushi, Hiroyuki
    Kanda, Junya
    Kobayashi, Masayuki
    Maeda, Takeshi
    Kitano, Toshiyuki
    Tsuji, Masaaki
    Ueda, Yasunori
    Ishikawa, Takayuki
    Nohgawa, Masaharu
    Watanabe, Mitsumasa
    Imada, Kazunori
    Moriguchi, Toshinori
    Itoh, Mitsuru
    Ohno, Hitoshi
    Yonezawa, Akihito
    Hirata, Hirokazu
    Arima, Nobuyoshi
    Asagoe, Kohsuke
    Anzai, Naoyuki
    Nagata, Kayoko
    Yasuno, Shinji
    Kuwabara, Yoshihiro
    Kitao, Hiromi
    Kim, Ihhwa
    Kawagishi, Kiyomi
    Ueshima, Kenji
    Tominari, Shinjiro
    Nakayama, Takeo
    Yamashita, Kouhei
    Takaori-Kondo, Akifumi
    HEMATOLOGY, 2022, 27 (01) : 239 - 248
12345